Acrivon Therapeutics, Inc. (ACRV)
Nasdaq: ACRV · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 19, 2026 | Mar 27, 2025 | Mar 28, 2024 | Mar 28, 2023 | · |
| Research and development | 59,990 | 63,992 | 46,024 | 23,949 | · |
| General and administrative | 24,124 | 25,207 | 21,079 | 8,708 | · |
| Total operating expenses | 84,114 | 89,199 | 67,103 | 32,657 | 16,184 |
| Operating income | -84,114 | -89,199 | -67,103 | -32,657 | -16,184 |
| Interest and investment income | · | · | 7,000 | 1,500 | · |
| Interest income (expense), net | 6,479 | 9,201 | 7,037 | · | · |
| Other income (expense), net | -270 | -558 | -322r | 1,490 | 21 |
| Total non-operating income (expense) | 6,209 | 8,643 | 6,715 | 1,490 | -59 |
| Income before income taxes | -77,825 | -80,444 | · | · | · |
| Income tax expense | 0 | · | · | · | · |
| Net income including non-controlling interests | -77,905 | -80,556 | -60,388 | -31,167 | -16,243 |
| Net income | -77,905 | -80,556 | -60,388 | -31,167 | -16,243 |
| Earnings per share, basic | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| Earnings per share, diluted | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 |
| Weighted average shares, basic | 38,509,281 | 33,791,817 | 22,078,190 | 4,121,912 | 1,743,382 |
| Weighted average shares, diluted | 38,509,281 | 33,791,817 | 22,078,190 | 4,121,912 | 1,743,382 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding